Home

Acute T cell lymphoblastic leukemia

T-cell Acute Lymphoblastic Leukaemia T-cell acute lymphoblastic leukaemia (T-ALL) is a specific type of leukaemia. It is a variant of acute lymphoblastic leukaemia (ALL), with features similar to some types of lymphoma. T-cell acute lymphoblastic leukaemia (T-ALL) is a type of acute leukaemia meaning that it is aggressive and progresses quickly Acute lymphocytic leukemia (ALL) is also called acute lymphoblastic leukemia. Acute means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. Lymphocytic means it develops from early (immature) forms of lymphocytes, a type of white blood cell Definition Acute lymphoblastic leukemia of T-cell origin. It comprises about 15% of childhood cases and 25% of adult cases. It is more common in males than females

T-cell Acute Lymphoblastic Leukaemia Leukaemia Car

T-cell acute lymphoblastic leukemia is a rapidly-moving type of cancer, so treatment is typically started immediately after diagnosis. Chemotherapy is a standard type of treatment for this disease. This involves the use of specialized drugs which contain strong chemicals designed to destroy cancer cells and slow the progression of the disease Childhood acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many immature lymphocytes (a type of white blood cell). Leukemia may affect red blood cells, white blood cells, and platelets. Past treatment for cancer and certain genetic conditions affect the risk of having childhood ALL It can be considered either a lymphoma or a type of acute lymphoblastic leukemia (ALL), depending on how much of the bone marrow is involved (leukemias have more bone marrow involvement). The cancer cells are very early forms of T cells T-cell acute lymphoblastic leukemia may refer to: T-lymphoblastic leukemia/lymphoma, a form of lymphoid leukemia and lymphoma Adult T-cell leukemia/lymphoma, a rare cancer of the immune system's own T-cells This disambiguation page lists articles associated with the title T-cell acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy characterized by aberrant proliferation of immature thymocytes. Despite an overall survival of 80% in the pediatric setting, 20% of patients with T-ALL ultimately die from relapsed or refractory disease. Therefore, there is an urgent need for novel therapies

What Is Acute Lymphocytic Leukemia (ALL)? Acute

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. Symptoms may include feeling tired, pale skin color, fever, easy bleeding or bruising, enlarged lymph nodes, or bone pain. As an acute leukemia, ALL progresses rapidly and is typically fatal within weeks or months if left untreated T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that has historically been associated with a very poor prognosis. Nevertheless, despite a lack of incorporation of novel agents, the development of intensified T-ALL-focused protocols has resulted in significant improvements in outcome in children T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant neoplasm of the bone marrow. It accounts for ∼20% of all cases of ALL and is somewhat more common in adults than children, although the incidence diminishes with older age. 1 Its clinical presentation can include hyperleukocytosis with extramedullary involvement of lymph nodes and other organs, including frequent central. Acute lymphocytic leukemia is also known as acute lymphoblastic leukemia. Acute lymphocytic leukemia is the most common type of cancer in children, and treatments result in a good chance for a cure. Acute lymphocytic leukemia can also occur in adults, though the chance of a cure is greatly reduced

TP53 is an inclusion eligibility criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [ 3 ] T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with an increased incidence in males 3. In this study, we report the identification of inactivating mutations.. T-Cell acute lymphoblastic leukemi symptoms The symptoms of T-ALL are basically the same as those found in other types of leukemia. We can only make an appropriate diagnosis by investigating further and using additional blood tests and bone marrow aspiration We measured Smad3 messenger RNA (mRNA) and protein in leukemia cells obtained at diagnosis from 19 children with acute leukemia, including 10 with T-cell acute lymphoblastic leukemia (ALL), 7 with.

T-cell acute lymphoblastic leukemia (Concept Id: C1961099

  1. But T-cell acute lymphoblastic leukemia (T-ALL) hits like a landslide. In most instances, it is a very urgent situation where we need to hospitalize people and get them going on treatment, says Dr. Mark Litzow, head of the acute leukemia group at Mayo Clinic in Rochester, Minnesota
  2. Adult T-cell leukemia/lymphoma (ATLL) is a rare and often aggressive (fast-growing) T-cell lymphoma that can be found in the blood (leukemia), lymph nodes (lymphoma), skin, or multiple areas of the body
  3. Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per year in the United States alone. The hallmark of ALL is chromosomal.
  4. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia Fractionated dosing of CTL019 with intrapatient dose modification optimizes safety without compromising efficacy in adults with r/r ALL
  5. Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males)
  6. METHODS: We measured Smad3 messenger RNA (mRNA) and protein in leukemia cells obtained at diagnosis from 19 children with acute leukemia, including 10 with T-cell acute lymphoblastic leukemia (ALL), 7 with pre-B-cell ALL, and 2 with acute nonlymphoblastic leukemia (ANLL). All nine exons of the SMAD3 gene (MADH3) were sequenced
  7. A team of researchers affiliated with multiple institutions in Germany and France has found that a subgroup of T-cell acute lymphoblastic leukemia (T-ALL) mouse models benefited from a targeted.

T-cell lymphoblastic lymphoma and T-cell acute

The prognosis depends on the type of leukemia, the extent of the disease, age of the patient, and the general condition of the patient.Some patients can go into complete remission. The average five-year survival rate of leukemia is 60-65%.. The survival rate of acute lymphoblastic leukemia (ALL) depends on the age of the patient and the response to chemotherapy Acute lymphoblastic leukemia (ALL) is a cancer that affects the white blood cells. These cells fight infection and help protect the body against disease. Patients with ALL have too many immature white blood cells in their bone marrow. These cells crowd out normal white blood cells. Without enough normal white blood cells, the body has a harder. Definition. (T-ALL) is a type of acute lymphoblastic leukemia (ALL), a cancer of the lymphocyte-forming cells called lymphoblasts. T-ALL is a neoplasm where blasts have committed to the T lineage. Click here for instructions on how to download the free FCS Express Reader to view and manipulate the sample cases. T Cell ALL case submitted by UTMC

T-Cell Acute Lymphoblastic Leukemia - Anti Leukemi

Acute lymphoblastic leukemia (ALL) is a neoplasm involving precursor lymphoblasts committed to either the B-cell or T-cell lineage. ALL is primarily a disease of children, with about 75% of cases. Acute lymphoblastic leukaemia (ALL) is a type of cancer that affects the blood and bone marrow. ALL is characterised by an overproduction of immature white blood cells, called lymphoblasts or leukaemic blasts. Because the bone marrow is unable to make adequate numbers of red cells, normal white cells and platelets, people with ALL become more. Among adults, B-cell lineage represents 75 percent of cases. T-cell lymphoblastic leukemia: This subtype of ALL originates in immature cells that would normally develop into T-cell lymphocytes. This subtype is less common, and it occurs more often in adults than in children. Among adults, T-cell lineage represents about 25 percent of cases Acute lymphoblastic leukemia (also called ALL) is a cancer of blood cells. It affects a type of white blood cell called a lymphocyte. ALL is also known as lymphoblastic lymphoma when the disease primarily involves lymph nodes rather than the blood and bone marrow Acute lymphocytic leukemia is the most common childhood cancer, although it can develop in adults, too. Learn about the acute lymphocytic leukemia survival rate here. Discover the factors that can.

Abstract: T-cell acute lymphoblastic leukemia is identified in 10-25% of all newly diagnosed acute lymphoblastic leukemia's in children. The disease results from cytogenetic and molecular abnormalities which disrupt key oncogenic, tumor suppressor, and developmental pathways which control normal thymocyte development Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Grabher C, von Boehmer H, Look AT: Nature reviews. Cancer. 2006 ; 6 (5) : 347-359. PMID 16612405 : Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia T-Cell Prolymphocytic Leukemia (T-PLL) Get Personalized Information & Support 1-800-955-4572 Live Chat Email; Taking part in a clinical trial may be the best treatment choice for some acute lymphoblastic leukemia (ALL) patients. Clinical trials are under way for patients at every treatment stage and for patients in remission Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan;68(1):e28719. Epub 2020 Oct 7. Erratum in: Pediatr Blood Cancer. 2021 Mar;68(3):e28885. link to original article contains verified protocol in supplement PubMe

T cell acute lymphoblastic leukemias (T-ALLs) are aggressive hematologic tumors resulting from the malignant transformation of T cell progenitors. T-ALL accounts for 10%-15% of pediatric and 25% of adult ALL cases ( 1) and is characteristically more frequent in males than females In general, treatment for acute lymphocytic leukemia falls into separate phases: Induction therapy. The purpose of the first phase of treatment is to kill most of the leukemia cells in the blood and bone marrow and to restore normal blood cell production. Consolidation therapy. Also called post-remission therapy, this phase of treatment is. Acute lymphocytic leukemia is a type of acute leukemia. It's also called ALL and acute lymphoblastic leukemia. Acute means that it usually gets worse quickly if it's not treated. ALL is the most common type of cancer in children. It can also affect adults Acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia of either B- or T-lineage immature lymphoid cells. ALL is primarily a childhood disease (ALL represents 75-80% of all acute leukemias in children ) and follows a bimodal distribution; the first peak occurs between 3 and 5 years of age and the second in adults older than 50 years

Acute lymphoblastic leukaemia is a type of cancer that affects white blood cells. It progresses quickly and aggressively and requires immediate treatment. Both adults and children can be affected. Acute lymphoblastic leukaemia is rare, with around 790 people diagnosed with the condition each year in the UK In the United States, the incidence of acute lymphoblastic leukemia (ALL) is approximately 1 in 50,000. ALL accounts for approximately 70% of all childhood leukemia cases (ages 0 to 19 years), making it the most common type of childhood cancer. Approximately 85% of pediatric cases of ALL are B-cell lineage (B-ALL) and 15% are T-cell lineage (T. Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing one quarter of all pediatric cancers. The annual incidence of acute lymphoblastic leukemia within the United States is 3.7-4.9 cases per 100,000 children age 0-14 years, [ 4] with a peak incidence in children aged 2-5 years

Acute lymphocytic leukemia is the most common childhood malignancy, whereas acute myeloid leukemia primarily affects adults. The underlying cause of acute leukemia is rarely identifiable, but risk factors include prior chemotherapy and radiation therapy , and hereditary syndromes such as Down syndrome For acute lymphoblastic leukemia (ALL), the 5-year survival rate has improved significantly since 1975. Get information about risk factors, signs, diagnosis, molecular features, survival, risk-based treatment assignment, and induction and postinduction therapy for children and adolescents with newly diagnosed and recurrent ALL N2 - T-cell acute lymphoblastic leukemia/lymphoma is an aggressive hematological neoplasm whose classification is still based on immunophenotypic findings. Frontline treatment encompass high intensity combination chemotherapy with good overall survival; however, relapsing/refractory patients have very limited options The CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021 drug pipelines has been added to ResearchAndMarkets.com's offering. This CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021, report provides comprehensive insights about 5. T-cell acute lymphoblastic leukemia (T-ALL) is an uncommon aggressive leukemia arising from the malignant transformation of hematopoietic progenitors primed toward T-cell development. T-ALL accounts for approximately 10% to 15% of pediatric and 25% of adult ALL cases, and is characteristically more frequent in male than female

Acute Lymphoblastic Leukemia (ALL): Symptoms, Diagnosis

Precursor T-cell Acute Lymphoblastic Leukemia - 2

What is T-Cell Lymphoblastic Lymphoma

  1. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up D Hoezler and others Annals of Oncology, 2016. Vol 27, Supplement 5, Pages 69-82. Cancer and its management (7th edition) J Tobias and D Hochhauser. Wiley Blackwell, 2015. Cancer - principles and practice of oncology (10th.
  2. Adult T cell acute lymphoblastic leukemia (T-ALL) is a rare disease that affects less than 10 individuals in one million. It has been less studied than its cognate pediatric malignancy, which is more prevalent. A higher percentage of the adult patients relapse, compared to children. It is thus essential to study the mechanisms of relapse of adult T-ALL cases
  3. T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are considered the same disease, differing by the extent of bone marrow infiltration. According to recent gene expression profiling data, T-ALL and T-LBL can be separated by prediction analysis of microarrays showing an overexpression of MML1 in T-LBL and CD47.
  4. imal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy. Leukemia.
  5. Childhood acute lymphoblastic leukemia (also called acute lymphocytic leukemia or ALL) is a cancer of the blood and bone marrow. This type of cancer usually gets worse quickly if it is not treated. It is the most common type of cancer in children. Normally, the bone marrow makes blood stem cells (immature cells) that become mature blood cells.
  6. Adult T-cell leukemia/lymphoma (ATLL). ATLL may be treated with zidovudine (Retrovir) and recombinant interferon alpha if it is in the chronic or acute phase. The goal of treatment is to strengthen the immune system and treat the human T-cell leukemia virus (HTLV). The lymphoma phase is usually treated with combination chemotherapy. Sezary.

What Is T-Cell Acute Lymphoblastic Leukemia? (with pictures

Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects both children and adults, with peak prevalence between the ages of 2 and 5 years. Steady progress in development of effective treatments has led to a cure rate of more than 80% in children, creating opportunities for innovative approaches that would preserve past gains in leukaemia-free survival while. Acute lymphoblastic lymphoma (ALL) is a very rare cancer that affects the blood cells and the immune system of the patient. Since it mainly occurs in people under the age of 35 and chiefly affects children-it is the most common cancer to affect children between the ages of 1 and 7-it is a disease that gets a lot of attention Find link is a tool written by Edward Betts.. searching for T-cell acute lymphoblastic leukemia 59 found (60 total) alternate case: t-cell acute lymphoblastic leukemia Acute leukemia (153 words) exact match in snippet view article find links to article leukemia Acute erythroid leukemia Acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia Adult T-cell leukemia/lymphoma (Precursor) T.

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ

Pediatric T-Cell Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia generally has a good prognosis. The 5-year survival rate is 85%-90% with treatment. If untreated, median survival is only 5 weeks, however. Prognosis depends on various factors, including the following (see also the table below): Age: Children have a better prognosis than adults Participants must have relapsed or refractory acute lymphoblastic leukemia or lymphoma (ALL): Stratum I: T-cell lymphoblastic leukemia or lymphoma in first relapse or refractory to one or two courses of frontline induction therapy. Stratum II: B-cell or T-cell lymphoblastic leukemia or lymphoma in second or third relapse or refractory to 2 or 3. Diagnosis of refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) according to the NCCN 2019.V2 Guideline. Refractory T-ALL is defined as a patient who has failed to achieve complete remission after induction therapy. Relapsed T-ALL is defined as the reappearance of blasts (5%) in either. Early T-cell precursor lymphoblastic leukemiab Abbreviations: ALL, acute lymphoblastic leukemia; WHO, World Health Organization. a On the basis of The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. 23 b Provisional entity

Types of T-cell Lymphom

  1. T-lymphoblastic leukemia / lymphoma (T-ALL) is a neoplasm of lymph oblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cell s with scant cytoplasm, moderately condensed to dispersed chromatin, and inconspicuous nucleoli, involving bone marrow and blood (T-ALL) or presenting with primary involvement of the.
  2. T-cell acute lymphoblastic leukemia/lymphoma is an aggressive hematological neoplasm whose classification is still based on immunophenotypic findings. Frontline treatment encompass high intensity combination chemotherapy with good overall survival; however, relapsing/refractory patients have very limited options. In the last years, the understanding of molecular physiopathology of this disease.
  3. ance

T-cell acute lymphoblastic leukemia - Wikipedi

T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted

Acute lymphoblastic leukemia - Wikipedi

Distinct DNA methylation signatures, related to different prognosis, have been observed across many cancers, including T-cell acute lymphoblastic leukemia (T-ALL), an aggressive hematological neoplasm. By global methylation analysis, two major phenotypes might be observed in T-ALL: hypermethylation related to better outcome and hypomethylation, which is a candidate marker of poor prognosis Acute lymphoblastic leukemia of T-cell origin. It comprises about 15% of childhood cases and 25% of adult cases. It is more common in males than females. (WHO, 2001) [ ] Synonyms: acute T cell lymphoblastic leukemia Leukemia Lymphoma, Adult T Cell Adult T-Cell Leukemias T-cell acute lymphoblastic leukaemia Acute T-Cell Lymphocytic Leukemia HTLV. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of leukemia in which too many T-cell lymphoblasts, or immature white blood cells, are found in the bone marrow and blood. T-cell acute lymphoblastic leukemia (T-ALL) is a hematological malignancy originating from T-lymphocytes in bone marrow. In recent years, with the advances of chemotherapy and the application of allogeneic hematopoietic stem cell transplantation in the management of T-ALL, the outcomes of this disease have been significantly improved

1. Introduction. T-cell acute lymphoblastic leukemia (T-ALL) is a clonal malignant disorder of immature T-cells that accounts for 10-15% of childhood and 25% of adult ALL patients [].Despite the relatively high morbidity and mortality of T-ALL when compared to B-cell ALL, the prognosis of T-ALL has dramatically improved following the advancement of chemotherapy, and its long-term survival. Lymphoblastic leukemia/lymphoma (LBL) is an aggressive subset of non-Hodgkin's lymphoma (NHL) that is derived from B or T-lymphoid progenitors . As a disease comparable to acute lymphoid leukemia (ALL), it represents 2%-4% of all adult NHL and the second most common subtype of NHL in children [2, 3]. With progress in chemotherapy in the.

T-cell acute lymphoblastic leukemia

Childhood acute lymphoblastic leukemia (C-ALL) is a common type of cancer in children. Like all leukemias, it is a cancer of blood-forming cells in the bone marrow. Symptoms and signs of C-ALL include. fever, bruising, bleeding, weakness, loss of appetite, and. painless lumps in the neck, groin, or armpits (enlarged lymph nodes ) Very rare cases of human T cell acute lymphoblastic leukemia (T-ALL) harbor chromosomal translocations that involve NOTCH1 , a gene encoding a transmembrane receptor that regulates normal T cell development. Here, we report that more than 50% of human T-ALLs, including tumors from all major molecular oncogenic subtypes, have activating mutations that involve the extracellular. Of the four primary types of leukemia, acute lymphoblastic leukemia (also known as acute lymphocytic leukemia or ALL) is the least common. About 6,000 new cases are diagnosed in the United States each year. While people of all ages develop ALL, a majority of new diagnoses are in people under age 20, making it the most common form of childhood. Acute Lymphoblastic Leukemia (ALL) Acute lymphoblastic leukemia (ALL) is a liquid tumor or cancer of the blood that starts in the bone marrow and spreads to the bloodstream (the term leukemia comes from Greek words for white and blood). ALL is the most common children's cancer, accounting for 35% of all cancers in children N Engl J Med. 2018;378(5):439-48 This is a pivotal, global study which led to approval of Tisagenlecleucel (anti-CD19 CAR-T cell) in relapsed refractory B cell acute lymphoblastic leukemia patients up to 25 years of age. 14. Erratum: Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release.

How I treat newly diagnosed T-cell acute lymphoblastic

People with acute lymphocytic leukemia (ALL) may have questions about their prognosis and survival. Prognosis and survival depend on many factors. Only a doctor familiar with a person's medical history, type of cancer, stage, characteristics of the cancer, treatments chosen and response to treatment can put all of this information together. ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TEACHING POINTS . Epidemiology 1. Leukemia accounts for ~31% of all childhood cancer occurring before age 15 years and about 25% of that which occurs before 20 years of age . 2. Overall, ALL comprises about 75% of childhood leukemia cases . 3. 3250 cases (2400 ALL) of leukemia/yr in US before age 20 . 4 The type of leukemia is determined by where the cell is in the stage of development when it becomes malignant, or cancerous. The stem cell matures into either the lymphoid or myeloid cells. The lymphoid cells mature into either B-lymphocytes or T-lymphocytes. If the leukemia is among these cells, it is called acute lymphoblastic leukemia (ALL)

Precursor T-cell Acute Lymphoblastic Leukemia - 3

How I treat T-cell acute lymphoblastic leukemia in adults

Study Design. The Group for Research on Adult Acute Lymphoblastic Leukemia 2005 (GRAALL-2005) trial was conducted between 2006 and 2014 at 56 French and 9 Swiss centers In T-cell acute lymphoblastic leukemia (T-ALL), transcription factors are known to be deregulated by chromosomal translocations. Graux et al. (2004) described the extrachromosomal (episomal) amplification of ABL1 in 5 of 90 (5.6%) individuals with T-ALL T cell acute lymphoblastic leukemia (T-ALL) is a high-risk subtype that comprises 10-15% of childhood and 20-25% of adult ALL cases. Over 70% of T-ALL patients harbor activating mutations in the NOTCH1 signaling pathway and are predicted to be sensitive to gamma-secretase inhibitors. We have recently demonstrated that selective inhibition of PSEN1-containing gamma-secretase complexes can. The market for acute lymphoblastic leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Owing to the rising focus of most of the pharmaceutical companies on oncology, it is expected that few new small-sized companies will also penetrate the market in the near future

Introduction. Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) accounts for about 17% of T-ALL and is highly aggressive. 1 Besides the concurrence of myeloid/stem cell signatures, this hematopoietic malignancy with B marker expression is exceptionally rare, and usually poses big challenges to diagnosis. Additionally, patients with infiltration of the breast were only sporadically. The use of haploidentical hematopoietic cell transplantation (haplo-HCT) with posttransplantation cyclophosphamide prophylaxis is gaining traction in patients with acute lymphoblastic leukemia (ALL). METHODS. The Acute Leukemia Working Party/European Society for Blood and Marrow Transplantation registry was used to evaluate the outcomes of.

Precursor T-cell Acute Lymphoblastic Leukemia - 5Gamma-Delta T Cell Acute Lymphoblastic Leukemia: A SinglePrecursor T-cell Acute Lymphoblastic Leukemia - 6T-Acute Lymphoblastic Leukemia with Plasmacytosis 2Minimal residual disease alone not predictive in T-cellPrecursor T-lymphoblastic Leukemia - 2